PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 27, 2026EJNMMI Research0 citationsOpen Access

Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with ¹⁷⁷LuLu-DOTA-TATE

FLFei LiuHYHongxing YangJZJianping Zhang

Key Points

  • This research investigates the relationship between absorbed doses and SUV from SPECT/CT imaging in patients treated for neuroendocrine tumors.
  • Compared treatment outcomes of Lutetium-177 and Octreotide in patients with GEP-NETs.
  • Utilized SPECT/CT imaging to measure absorbed dose and SUV.
  • Analyzed dose-response relationships based on imaging results.
  • Found significant correlations between absorbed dose and SUV.
  • Indicated favorable responses in patients treated with Lutetium-177.
  • Demonstrated improved treatment efficacy compared to Octreotide.

Abstract

A Study Comparing Treatment With Lutetium177Lu Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs, NCT05459844. Registered 5 July 2022, https://clinicaltrials.gov/study/NCT05459844?cond=NCT05459844&rank=1.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/69a134fbed1d949a99abe6d8https://doi.org/10.1186/s13550-026-01402-2
Ask AI
Helpful
Bookmark
Share
View Full Paper